Combinations and modes of administration of therapeutic agents and combination therapy
AssigneeAbraxis BioScience, LLC
InventorsNeil P. Desai, Patrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Claims77
A method of treating melanoma in a human individual, comprising administering to the individual:
- a) an effective amount of a composition comprising nanoparticles comprising taxane coated with albumin, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm, and b) an effective amount of an anti-VEGF antibody, wherein the effective amount of the taxane in the composition is about 60 mg/m2 to about 300 mg/m2.
A method of inhibiting tumor metastasis in an individual having melanoma, comprising administering to the individual:
- a) an effective amount of a composition comprising nanoparticles comprising taxane coated with albumin, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm, and b) an effective amount of an anti-VEGF antibody, wherein the effective amount of the taxane in the composition is about 60 mg/m2 to about 300 mg/m2.
A kit comprising:
- a) a composition comprising nanoparticles comprising a taxane coated with albumin, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm, b) an anti-VEGF antibody, and c) instructions for administering an effective amount of the nanoparticles and the anti-VEGF antibody to a human individual for treatment of melanoma, wherein the effective amount of the taxane in the composition is about 60 mg/m2 to about 300 mg/m2.
Dependencies are inferred from the claim text.